<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00538005</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000551557</org_study_id>
    <secondary_id>POHA-0603</secondary_id>
    <nct_id>NCT00538005</nct_id>
  </id_info>
  <brief_title>Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma</brief_title>
  <official_title>A Phase I/II Trial of Nexavar, Avastin and Eloxatin in Patients With Metastatic Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>San Diego Pacific Oncology &amp; Hematology Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in&#xD;
      different ways. Some block the ability of tumor cells to grow and spread. Others find tumor&#xD;
      cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop&#xD;
      the growth of malignant melanoma by blocking blood flow to the tumor. Drugs used in&#xD;
      chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells,&#xD;
      either by killing the cells or by stopping them from dividing. Giving sorafenib together with&#xD;
      bevacizumab and oxaliplatin may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side-effects and best dose of sorafenib when&#xD;
      given together with bevacizumab and oxaliplatin and to see how well it works in treating&#xD;
      patients with metastatic malignant melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To determine the maximum tolerated dose of sorafenib tosylate when administered with&#xD;
           bevacizumab and oxaliplatin.&#xD;
&#xD;
        -  To determine the effect of this treatment regimen on the complete and partial response&#xD;
           rate in patients with metastatic melanoma.&#xD;
&#xD;
        -  To determine the effect of this treatment regimen on the progression-free and overall&#xD;
           survival of patients with metastatic melanoma.&#xD;
&#xD;
      OUTLINE: This is a phase I dose-escalation study of sorafenib tosylate followed by a phase II&#xD;
      study.&#xD;
&#xD;
        -  Phase I: Patients receive bevacizumab IV over 30-90 minutes and oxaliplatin IV over 2&#xD;
           hours on day 1. Patients also receive oral sorafenib tosylate twice daily on days 1-14.&#xD;
           Treatment repeats every 2 weeks in the absence of disease progression or unacceptable&#xD;
           toxicity.&#xD;
&#xD;
        -  Phase II: Patients receive sorafenib tosylate at the maximum tolerated dose and&#xD;
           bevacizumab and oxaliplatin as in phase I.&#xD;
&#xD;
      After completion of study therapy, patients are followed for at least 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2007</start_date>
  <primary_completion_date type="Anticipated">July 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of sorafenib tosylate when administered with bevacizumab and oxaliplatin</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response (complete and partial) as assessed by RECIST criteria</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed melanoma&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
          -  Measurable or evaluable non-CNS disease&#xD;
&#xD;
               -  Measurable disease, defined as a unidimensionally measurable lesion as determined&#xD;
                  by physical exam, x-ray, CT scan, MRI, or other radiographic procedure&#xD;
&#xD;
               -  Evaluable disease, defined as a lesion that can be seen radiographically but is&#xD;
                  not unidimensionally measurable&#xD;
&#xD;
                    -  Previously irradiated lesions with documented progression are allowed&#xD;
                       provided there are no other sites of metastatic disease&#xD;
&#xD;
          -  No active brain metastases&#xD;
&#xD;
               -  Previously treated, responding brain metastases allowed, provided there is&#xD;
                  measurable disease outside of the CNS&#xD;
&#xD;
                    -  At least 3 weeks since prior chemotherapy and 6 weeks since prior&#xD;
                       radiotherapy for CNS disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  ANC ≥ 1,200/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Bilirubin ≤ 3.0 mg/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  EKG with no evidence of serious arrhythmia or recent myocardial infarction&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Chronic underlying immunodeficiency disease&#xD;
&#xD;
          -  Other serious concurrent illness&#xD;
&#xD;
          -  Other forms of cancer within 5 years of initial diagnosis except nonmelanoma skin&#xD;
             cancer and cervical cancer&#xD;
&#xD;
          -  Congestive heart failure or myocardial infarction within the past 6 months&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 6 weeks since prior radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior surgery&#xD;
&#xD;
          -  Prior biologic therapy allowed&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Prior cytotoxic agents&#xD;
&#xD;
          -  Prior sorafenib tosylate, bevacizumab, or oxaliplatin&#xD;
&#xD;
          -  Concurrent biological therapy, except growth factors for anemia, neutropenia, or&#xD;
             thrombocytopenia&#xD;
&#xD;
          -  Concurrent radiotherapy, chemotherapy, or surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward F. McClay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Diego Pacific Oncology &amp; Hematology Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Diego Pacific Oncology and Hematology Associates, Incorporated - Encinitas</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward F. McClay, MD</last_name>
      <phone>760-452-3340</phone>
      <email>emcclay@pacificoncology.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>October 1, 2007</study_first_submitted>
  <study_first_submitted_qc>October 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2007</study_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

